Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres
- PMID: 26833536
- DOI: 10.1111/ene.12941
Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres
Abstract
Background and purpose: Our objective was to evaluate the extent to which the 2005 recommendations of the European Federation of Neurological Sciences (EFNS) on the multidisciplinary management of amyotrophic lateral sclerosis (ALS) are followed in clinical practice.
Methods: This was a multicentre observational study involving six French ALS referral centres receiving prevalent and incident cases. Recommendations were translated into ad hoc questions referring to key aspects of management, and their application was evaluated by a clinical research assistant who independently examined the medical charts (MCs). When necessary, an independent board-certified neurologist answered the questions based on examination of the MC and interview of the caring neurologist. Questions regarding diagnosis and communication were put to patients in a self-administered questionnaire.
Results: In all, 376 patients [176 incident, 200 prevalent cases; median age at diagnosis 62.8 years (interquartile range 55.7-72.3); sex ratio 1.37; 27.3% bulbar onset] were included. All the topics covered in the recommendations were evaluated: diagnostic delay (e.g. mean 13.6 months, associated with age and onset); breaking the news (e.g. criteria for communication quality were satisfactory in more than 90%); multidisciplinary and sustained support (e.g. clinic visits were scheduled every 2-3 months in 90%). Also considered were whether riluzole had been offered, symptom management, genetic testing, ventilation, communication defects, enteral nutrition, palliative and end-of-life care. Characteristics associated with poor compliance with some guidelines (schedule of visits, delayed riluzole initiation) were also identified.
Conclusion: This is the first evaluation of the application of the EFNS recommendations for the management of ALS in a nationwide sample. The results allow us to highlight areas for improvement.
Keywords: access and evaluation; amyotrophic lateral sclerosis; clinical audit; healthcare quality; practice guideline.
© 2016 EAN.
Similar articles
-
[Diagnosis and treatment of amyotrophic lateral sclerosis according to EFNS recommendations (2005)].Neurol Neurochir Pol. 2007 Sep-Oct;41(5):445-56. Neurol Neurochir Pol. 2007. PMID: 18033645 Review. Polish.
-
Outcomes research in amyotrophic lateral sclerosis: lessons learned from the amyotrophic lateral sclerosis clinical assessment, research, and education database.Ann Neurol. 2009 Jan;65 Suppl 1:S24-8. doi: 10.1002/ana.21556. Ann Neurol. 2009. PMID: 19191307
-
Factors affecting the diagnostic delay in amyotrophic lateral sclerosis.Clin Neurol Neurosurg. 2012 Jul;114(6):550-4. doi: 10.1016/j.clineuro.2011.11.026. Epub 2011 Dec 14. Clin Neurol Neurosurg. 2012. PMID: 22169158
-
EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.Eur J Neurol. 2012 Mar;19(3):360-75. doi: 10.1111/j.1468-1331.2011.03501.x. Epub 2011 Sep 14. Eur J Neurol. 2012. PMID: 21914052
-
Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4. Neurology. 2009. PMID: 19822873 Free PMC article. Review.
Cited by
-
Methods for informing people with amyotrophic lateral sclerosis/motor neuron disease of their diagnosis.Cochrane Database Syst Rev. 2023 Feb 22;2(2):CD007593. doi: 10.1002/14651858.CD007593.pub2. Cochrane Database Syst Rev. 2023. PMID: 36812393 Free PMC article.
-
Pharmacological and non-pharmacological treatments in amyotrophic lateral sclerosis: an Italian real-world data study.Eur J Neurol. 2024 Dec;31(12):e16470. doi: 10.1111/ene.16470. Epub 2024 Sep 19. Eur J Neurol. 2024. PMID: 39297678 Free PMC article.
-
Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach.J Multidiscip Healthc. 2017 May 19;10:205-215. doi: 10.2147/JMDH.S134992. eCollection 2017. J Multidiscip Healthc. 2017. PMID: 28579792 Free PMC article. Review.
-
From suspicion to diagnosis: exploration strategy for suspected amyotrophic lateral sclerosis.Ann Med. 2024 Dec;56(1):2398199. doi: 10.1080/07853890.2024.2398199. Epub 2024 Sep 5. Ann Med. 2024. PMID: 39233624 Free PMC article. Review.
-
Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology.Neurology. 2023 Aug 1;101(5):223-232. doi: 10.1212/WNL.0000000000207166. Neurology. 2023. PMID: 37524529 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous